

CITATION REPORT

List of articles citing

A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus.
The Canadian Hydroxychloroquine Study Group

DOI: 10.1191/096120398678919778

Lupus, 1998, 7, 80-5.

Source: <https://exaly.com/paper-pdf/29631961/citation-report.pdf>

Version: 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
234	Hydroxychloroquine: past, present, future. <i>Lupus</i> , 1998 , 7, 65-7	2.6	30
233	Methodological issues of corticosteroid use in SLE clinical trials. <i>Lupus</i> , 1999 , 8, 692-7	2.6	12
232	Lupus patients in an emergency unit. Causes of consultation, hospitalization and outcome. A cohort study. <i>Lupus</i> , 2000 , 9, 601-6	2.6	61
231	How accelerated atherosclerosis in SLE has changed our management of the disorder. <i>Lupus</i> , 2000 , 9, 228-31	2.6	18
230	Systemic Therapy. 2000 , 1747-1766		1
229	Systemic lupus erythematosus in the elderly. 2000 , 26, 475-92		30
228	Effect of anti-beta2glycoprotein I Lupus Anticoagulants on fibrin polymerization and fibrinolysis. 2000 , 32, 39-44		3
227	Hopkins Lupus Cohort. 1999 update. 2000 , 26, 199-213, v		91
226	Treatment of systemic lupus erythematosus. 2001 , 1, 1065-75		22
225	Systemic lupus erythematosus: current management. 2001 , 175, 125-6		
224	Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study. <i>Lupus</i> , 2001 , 10, 401-4	2.6	275
223	Antimalarial therapy: a panacea for mild lupus?. <i>Lupus</i> , 2001 , 10, 148-51	2.6	26
222	Protective effect of hydroxychloroquine in systemic lupus erythematosus. Prospective long-term study of an Israeli cohort. <i>Lupus</i> , 2002 , 11, 356-61	2.6	105
221	Quinacrine added to ongoing therapeutic regimens attenuates anticardiolipin antibody production in SLE. <i>Lupus</i> , 2003 , 12, 297-301	2.6	12
220	Rheumatologic Diseases. 2003 , 573-619		0
219	Chloroquine gestational use in systemic lupus erythematosus: assessing the risk of child ototoxicity by pure tone audiometry. <i>Lupus</i> , 2004 , 13, 223-7	2.6	31
218	Update on the immunology, diagnosis and management of systemic lupus erythematosus. 2004 , 34, 338-47		15

217	Principes généraux des traitements du lupus érythémateux systémique et mesures préventives. 2005 , 72, 537-545		
216	New therapies for systemic lupus erythematosus. 2005 , 140, 205-12		39
215	Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. 2005 , 52, 1473-80		261
214	Antimalarials. 2005 , 347-372		
213	[Systemic lupus erythematosus]. 2005 , 130, 2451-8; quiz 2459-60, 2461-2		1
212	[Synthetic antimalarials]. 2005 , 132, 665-74		5
211	Cutaneous Lupus Erythematosus. 2005 ,		11
210	Pregnancy and Systemic Lupus Erythematosus. 2005 , 4, 43-57		
209	[Antimalarials: an update in rheumatic diseases]. 2006 , 2, 190-201		8
208	Cutaneous vasculitis: diagnosis and management. 2006 , 24, 414-29		111
207	Hydroxychloroquine in lupus pregnancy. 2006 , 54, 3640-7		362
206	Mycophenolate mofetil and systemic lupus erythematosus. <i>Lupus</i> , 2006 , 15, 44-54	2.6	5
205	Discontinuation rate and factors predictive of the use of hydroxychloroquine in LUMINA, a multiethnic US cohort (LUMINA XL). <i>Lupus</i> , 2006 , 15, 700-4	2.6	7
204	Hydroxychloroquine use predicts complete renal remission within 12 months among patients treated with mycophenolate mofetil therapy for membranous lupus nephritis. <i>Lupus</i> , 2006 , 15, 366-70	2.6	129
203	Antimalarials in systemic lupus erythematosus: benefits beyond disease activity. 2006 , 1, 225-233		5
202	Therapy of cutaneous lupus erythematosus. 2006 , 1, 105-120		2
201	Systemic lupus erythematosus: clinical manifestations, treatment and economics. 2006 , 6, 563-75		8
200	Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L). <i>Annals of the Rheumatic Diseases</i> , 2007 , 66, 1168-72	2.4	320

199	Hydroxychloroquine sulfate treatment is associated with later onset of systemic lupus erythematosus. <i>Lupus</i> , 2007 , 16, 401-9	2.6	126
198	Chloroquine increases low-density lipoprotein removal from plasma in systemic lupus patients. <i>Lupus</i> , 2007 , 16, 273-8	2.6	44
197	New concepts in antimalarial use and mode of action in dermatology. 2007 , 20, 160-74		185
196	[Modern therapy for systemic lupus erythematosus]. 2007 , 66, 662-6, 668-71		4
195	The biology behind the new therapies for SLE. 2007 , 61, 2113-9		19
194	[Hydroxychloroquine and systemic lupus: a reappraisal]. 2008 , 29, 735-7		9
193	Previous antimalarial therapy in patients diagnosed with lupus nephritis: influence on outcomes and survival. <i>Lupus</i> , 2008 , 17, 281-8	2.6	120
192	EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. <i>Annals of the Rheumatic Diseases</i> , 2008 , 67, 195-205	2.4	493
191	Learning from past mistakes: assessing trial quality, power and eligibility in non-renal systemic lupus erythematosus randomized controlled trials. 2008 , 47, 1367-72		15
190	Systemic Lupus Erythematosus. 2008 , 303-338		6
189	Hydroxychloroquine directly reduces the binding of antiphospholipid antibody-beta2-glycoprotein I complexes to phospholipid bilayers. 2008 , 112, 1687-95		166
188	Late-onset lupus: facts and fiction. 2008 , 3, 351-356		3
187	Lupus arthritis. 2009 , 23, 495-506		79
186	Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort. 2009 , 61, 830-9		175
185	Pregnancy and rheumatic disease: "by the book" or "by the doc". 2009 , 28, 1-9		24
184	Systemic lupus erythematosus in the elderly: antimalarials in disease remission. 2009 , 29, 1087-90		6
183	[Antimalarials. A treatment option for every lupus patient!?.] 2009 , 68, 584, 586-90		4
182	Systemic Lupus Erythematosus. 2009 , 131-159		2

181	Developments in the clinical understanding of lupus. 2009 , 11, 245		30
180	Systemic Lupus Erythematosus: A Therapeutic Update. 2009 , 22, 29-52		1
179	Factors associated with osteonecrosis in Thai lupus patients: a case control study. 2009 , 15, 345-9		22
178	Hydroxychloroquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: evidence for a novel effect for an old antimalarial drug. 2010 , 115, 2292-9		179
177	Perspectives on the management of late-onset systemic lupus erythematosus. 2010 , 6, 475-480		
176	The administration of low doses of rituximab followed by hydroxychloroquine, prednisone and low doses of mycophenolate mofetil is an effective therapy in Latin American patients with active systemic lupus erythematosus. 2010 , 10, 108-11		29
175	Hydroxychloroquine treatment in a community-based cohort of patients with systemic lupus erythematosus. <i>Arthritis Care and Research</i> , 2010 , 62, 386-92	4-7	29
174	Possible protective effect of hydroxychloroquine on delaying the occurrence of integument damage in lupus: LXXI, data from a multiethnic cohort. <i>Arthritis Care and Research</i> , 2010 , 62, 393-400	4-7	43
173	Nucleic acid sensing receptors in systemic lupus erythematosus: development of novel DNA- and/or RNA-like analogues for treating lupus. 2010 , 161, 208-22		23
172	Therapy: Hydroxychloroquine in SLE: old drug, new perspectives. 2010 , 6, 10-1		31
171	The annexin A5-mediated pathogenic mechanism in the antiphospholipid syndrome: role in pregnancy losses and thrombosis. <i>Lupus</i> , 2010 , 19, 460-9	2.6	103
170	A new role for antimalarials in systemic lupus erythematosus treatment. 2010 , 5, 299-312		1
169	Interferon-alpha: a therapeutic target in systemic lupus erythematosus. 2010 , 36, 173-86, x		49
168	Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 20-8	2.4	645
167	The management of systemic lupus erythematosus: Facts and controversies. 2010 , 28, 330-6		7
166	Autologous hematopoietic stem cell transplantation for childhood autoimmune disease. 2010 , 57, 239-71		26
165	Treatment approaches to juvenile dermatomyositis (JDM) across North America: The Childhood Arthritis and Rheumatology Research Alliance (CARRA) JDM Treatment Survey. 2010 , 37, 1953-61		76
164	The role of antimalarial agents in the treatment of SLE and lupus nephritis. 2011 , 7, 718-29		166

163	Hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis and its safety in pregnancy. 2011 , 10, 705-14		61
162	Interferon-Alpha in Systemic Lupus Erythematosus. 2011 , 307-320		
161	Antimalarials and SLE. 2011 , 1061-1081		0
160	SYSTEMIC LUPUS ERYTHEMATOSUS. 2011 , 315-343		20
159	Hydroxychloroquine reduces binding of antiphospholipid antibodies to syncytiotrophoblasts and restores annexin A5 expression. 2011 , 205, 576.e7-14		47
158	Juvenile systemic lupus erythematosus: review of clinical features and management. 2011 , 48, 879-87		20
157	Treatment of mild, moderate, and severe lupus erythematosus: focus on new therapies. 2011 , 13, 308-16		21
156	Geriatric Rheumatology. 2011 ,		6
155	Kidney. 2011 , 769-814		8
154	Dr. Laskari, et al reply. 2011 , 38, 2491.1-2491		
153	Belimumab in systemic lupus erythematosus: an update for clinicians. 2012 , 3, 11-23		9
152	Healthcare quality in systemic lupus erythematosus: using Donabedian's conceptual framework to understand what we know. 2012 , 7, 95-107		7
151	Effect of hydroxychloroquine treatment on pro-inflammatory cytokines and disease activity in SLE patients: data from LUMINA (LXXV), a multiethnic US cohort. <i>Lupus</i> , 2012 , 21, 830-5	2.6	113
150	Chapter 12: Lupus nephritis. 2012 , 2, 221-232		53
149	References. 2012 , 2, 259-274		9
148	Lupus nephritis: a critical review. 2012 , 12, 174-94		167
147	Recent progress in the treatment of lupus nephritis. 2012 , 22, 803-813		7
146	Maculopathy in patient with systemic lupus erythematosus treated with hydroxychloroquine. 2012 , 8, 280-3		3

145	Maculopathy in Patient With Systemic Lupus Erythematosus Treated With Hydroxychloroquine. 2012 , 8, 280-283		
144	Rheumatologie aus der Praxis. 2012 ,		1
143	Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 1771-82	2.4	692
142	Recommendations for diagnosis and treatment Treatment of systemic lupus erythematosus. Part I. Guidelines for the treatment of systemic lupus erythematosus. 2012 , 5, 383-389		1
141	Hydroxychloroquine: from malaria to autoimmunity. 2012 , 42, 145-53		348
140	Insights into the pathophysiology of the antiphospholipid syndrome provided by atomic force microscopy. 2012 , 43, 851-62		7
139	Hydroxychloroquine and smoking in patients with cutaneous lupus erythematosus. 2012 , 37, 327-34		32
138	Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials. 2013 , 65, 2143-53		119
137	Generalized Skin Hyperpigmentation and Longitudinal Melanonychia Secondary to Treatment With Hydroxychloroquine in Systemic Lupus Erythematosus. 2013 , 9, 381-382		2
136	Hiperpigmentaci3n cut3nea generalizada y melanoniquia longitudinal secundarias al tratamiento con hidroxiclороquina en lupus eritematoso sist3mico. 2013 , 9, 381-382		9
135	Overview of lupus nephritis management guidelines and perspective from Asia. 2013 , 16, 625-36		25
134	Recent progress in conventional and biologic therapy for systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72 Suppl 2, ii66-8	2.4	7
133	Antimalarial Medications. 2013 , 601-608		3
132	Systemic lupus erythematosus: an update on current pharmacotherapy and future directions. 2013 , 13, 723-37		19
131	[Treatment of systemic lupus erythematosus: myths, certainties and doubts]. 2013 , 141, 533-42		8
130	Multifaceted effects of hydroxychloroquine in human disease. <i>Seminars in Arthritis and Rheumatism</i> , 2013 , 43, 264-72	5.3	88
129	The early protective effect of hydroxychloroquine on the risk of cumulative damage in patients with systemic lupus erythematosus. 2013 , 40, 831-41		79
128	Mortality in SLE. 2013 , 666-675		2

127	Update on the treatment of lupus nephritis. 2013 , 22, 224-30		21
126	Factors associated with blood hydroxychloroquine level in lupus patients: renal function could be important. <i>Lupus</i> , 2013 , 22, 541-2	2.6	23
125	Systemic Lupus Erythematosus. 2013 , 803-819		
124	A cross-sectional study of hydroxychloroquine concentrations and effects in people with systemic lupus erythematosus. 2013 , 43, 547-53		15
123	The biological and clinical activity of anti-malarial drugs in autoimmune disorders. 2013 , 9, 45-62		27
122	Systemic lupus erythematosus: which drugs and when?. 2014 , 9, 385-394		4
121	Pharmacology of Chloroquine and Hydroxychloroquine. 2014 , 35-63		65
120	Overview of lupus nephritis management guidelines and perspective from Asia. 2014 , 19, 11-20		48
119	Antipalúdicos en dermatologí: mecanismo de acci3n, indicaciones y efectos secundarios. 2014 , 105, 243-252		27
118	Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 958-67	2.4	388
117	Ten common mistakes in the management of lupus nephritis. 2014 , 63, 667-76		28
116	Antimalarials in dermatology: mechanism of action, indications, and side effects. 2014 , 105, 243-52		14
115	Hydroxychloroquine: a multifaceted treatment in lupus. 2014 , 43, e167-80		101
114	Neutrophil Extracellular Trap Mitochondrial DNA and Its Autoantibody in Systemic Lupus Erythematosus and a Proof-of-Concept Trial of Metformin. 2015 , 67, 3190-200		166
113	Treat-to-target in lupus: what does the future hold?. 2015 , 10, 461-477		2
112	Consensus of the Brazilian Society of Rheumatology for the diagnosis, management and treatment of lupus nephritis. 2015 , 55, 1-21		3
111	The clinically quiescent phase in early-diagnosed SLE patients: inception cohort study. 2015 , 54, 868-75		13
110	Impact of hydroxychloroquine on preterm delivery and intrauterine growth restriction in pregnant women with systemic lupus erythematosus: a descriptive cohort study. <i>Lupus</i> , 2015 , 24, 1384-91	2.6	69

109	Reviewing the recommendations for lupus in children. 2015 , 17, 17		9
108	Systemic lupus erythematosus: review of synthetic drugs. 2015 , 16, 2793-806		14
107	[Consensus of the Brazilian Society of Rheumatology for the diagnosis, management and treatment of lupus nephritis]. 2015 , 55, 1-21		30
106	Antimalarials in the treatment of systemic lupus erythematosus: a registry-based cohort study in Denmark. <i>Lupus</i> , 2015 , 24, 299-306	2.6	12
105	Treatment of severe lupus nephritis: the new horizon. 2015 , 11, 46-61		67
104	Childhood onset systemic lupus erythematosus: how is it different from adult SLE?. 2015 , 18, 182-91		39
103	[Hydroxychloroquine for autoimmune diseases]. 2016 , 144, 232-40		13
102	Hydroxychloroquine in Systemic Lupus Erythematosus: Comment on the Article by Muangchan et al. <i>Arthritis Care and Research</i> , 2016 , 68, 1052-3	4.7	0
101	Cumulative immunosuppressant exposure is associated with diversified cancer risk among 14 832 patients with systemic lupus erythematosus: a nested case-control study. 2017 , 56, 620-628		21
100	Anti-malarials: Are There Benefits Beyond Mild Disease?. 2016 , 2, 1-12		5
99	Connective Tissue Disease. 2016 ,		1
98	Conventional Treatment of Systemic Lupus Erythematosus. 2016 , 213-238		
97	Immunosuppressive treatment for pure membranous lupus nephropathy in a Hispanic population. 2016 , 35, 2219-27		11
96	Risk of Serious Infection for Patients with Systemic Lupus Erythematosus Starting Glucocorticoids with or without Antimalarials. 2016 , 43, 1503-9		33
95	Reproductive outcomes following hydroxychloroquine use for autoimmune diseases: a systematic review and meta-analysis. 2016 , 81, 835-48		56
94	Analysis of Complete Remission in Systemic Lupus Erythematosus Patients Over a 32-Year Period. <i>Arthritis Care and Research</i> , 2016 , 68, 981-7	4.7	42
93	Systemic Lupus Erythematosus. 2016 , 285-317.e14		15
92	Pharmacological Management of Childhood-Onset Systemic Lupus Erythematosus. 2016 , 18, 181-95		16

91	Features associated with hematologic abnormalities and their impact in patients with systemic lupus erythematosus: Data from a multiethnic Latin American cohort. <i>Seminars in Arthritis and Rheumatism</i> , 2016 , 45, 675-83	5.3	34
90	Risk factors to predict the development of chronic kidney disease in patients with lupus nephritis. <i>Lupus</i> , 2017 , 26, 1139-1148	2.6	11
89	Effects of Hydroxychloroquine in Patients With Cutaneous Lupus Erythematosus: A Multicenter, Double-Blind, Randomized, Parallel-Group Trial. 2017 , 69, 791-799		54
88	Pediatric Lupus Nephritis. 2017 , 345-363		
87	Illustrative Cases of Kidney Disease Unique to Women. 2017 , 37, 412-416		0
86	Hydroxychloroquine dosing in immune-mediated diseases: implications for patient safety. 2017 , 37, 1611-16186		
85	Clinicians approaches to management of background treatment in patients with SLE in clinical remission: results of an international observational survey. <i>Lupus Science and Medicine</i> , 2017 , 4, e000173 ^{4.6}		14
84	Implementation of recommendations for the screening of hydroxychloroquine retinopathy: poor adherence of rheumatologists and ophthalmologists. <i>Lupus</i> , 2017 , 26, 277-281	2.6	10
83	Lipid Profiles in Systemic Lupus Erythematosus- An Update. 2017 , 39, 88-92		
82	Pediatric Systemic Lupus Erythematosus, Juvenile Dermatomyositis, Scleroderma, and Vasculitis. 2017 , 1844-1875.e8		1
81	Effects of Hydroxychloroquine on Proteinuria in Immunoglobulin A Nephropathy. 2018 , 47, 145-152		15
80	Double-Edged Effect of Hydroxychloroquine on Human Umbilical Cord-Derived Mesenchymal Stem Cells Treating Lupus Nephritis in MRL/lpr Mice. 2018 , 15, 1800-1813		9
79	The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults. 2018 , 57, e1-e45		150
78	Hydroxychloroquine desensitization, an effective method to overcome hypersensitivity-a multicenter experience. <i>Lupus</i> , 2018 , 27, 703-707	2.6	10
77	More Consistent Antimalarial Intake in First 5 Years of Disease Is Associated with Better Prognosis in Patients with Systemic Lupus Erythematosus. 2018 , 45, 90-94		12
76	Chloroquine and hydroxychloroquine are associated with reduced cardiovascular risk: a systematic review and meta-analysis. 2018 , 12, 1685-1695		53
75	Practice Variations in the Diagnosis, Monitoring, and Treatment of Systemic Lupus Erythematosus in Canada. 2018 , 45, 1440-1447		10
74	Systemic Lupus Erythematosus for Primary Care. 2018 , 45, 257-270		1

73	Adherence to hydroxychloroquine improves long-term survival of patients with systemic lupus erythematosus. 2018 , 57, 1743-1751		23
72	Les traitements du lupus systémique : retour vers le futur. 2019 , 86, 573-581		
71	Juvenile-onset systemic lupus erythematosus: Update on clinical presentation, pathophysiology and treatment options. 2019 , 209, 108274		39
70	10 most important contemporary challenges in the management of SLE. <i>Lupus Science and Medicine</i> , 2019 , 6, e000303	4.6	33
69	Impact of antimalarial (AM) on serum lipids in systemic lupus erythematosus (SLE) patients: A systematic review and meta-analysis. 2019 , 98, e15030		14
68	Real-world electronic health record identifies antimalarial underprescribing in patients with lupus nephritis. <i>Lupus</i> , 2019 , 28, 977-985	2.6	3
67	Lupus Nephritis (Including Antiphospholipid Antibody Syndrome), Pediatric. 2019 , 265-300		
66	Glomerular Diseases in Pregnancy. 2019 , 809-835		
65	Lupus Nephritis: Duration of Therapy and Possibility of Withdrawal. 2019 , 26, 387-392		3
64	Antimalarial Medications. 2019 , 650-660		
63	Epidemiology and Management of Lupus Nephritis. 2019 , 727-744		1
62	Prognosis and Mortality of SLE. 2019 , 770-781		
61	New therapeutic strategies in systemic lupus erythematosus management. 2019 , 15, 30-48		58
60	Advances in the treatment of systemic lupus erythematosus: From back to the future, to the future and beyond. 2019 , 86, 429-436		15
59	Treatment of systemic lupus erythematosus: don't forget hydroxychloroquine. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, e133	2.4	2
58	Prevalence and predictors of flare after immunosuppressant discontinuation in patients with systemic lupus erythematosus in remission. 2020 , 59, 1591-1598		18
57	Hydroxychloroquine and maintenance immunosuppression use in kidney transplant recipients: Analysis of linked US registry and claims data. 2020 , 34, e14118		2
56	Hydroxychloroquine and COVID-19: critiquing the impact of disease public profile on policy and clinical decision-making. 2020 , 46, 574-578		8

55	Recent Clinical and Preclinical Studies of Hydroxychloroquine on RNA Viruses and Chronic Diseases: A Systematic Review. 2020 , 25,		2
54	American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic: Version 2. 2020 , 72, e1-e12		49
53	Systemic lupus Erythematosus activity and Hydroxychloroquine use before and after end-stage renal disease. 2020 , 21, 450		0
52	Rheumatologists' perspective on hydroxychloroquine guidelines. <i>Lupus Science and Medicine</i> , 2020 , 7,	4.6	1
51	Ocular flare-up in patients with systemic lupus erythematosus following discontinuation of hydroxychloroquine. <i>Lupus</i> , 2020 , 29, 987-992	2.6	2
50	Revisiting hydroxychloroquine and chloroquine for patients with chronic immunity-mediated inflammatory rheumatic diseases. 2020 , 60, 32		24
49	American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic: Version 1. 2020 , 72, 1241-1251		105
48	Possible Consequences of a Shortage of Hydroxychloroquine for Patients with Systemic Lupus Erythematosus amid the COVID-19 Pandemic. 2020 , 47, 787-790		23
47	Clinical Significance of Monitoring Hydroxychloroquine Levels in Patients With Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis. <i>Arthritis Care and Research</i> , 2021 , 73, 707-716	4.7	9
46	American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic: Version 3. 2021 , 73, e1-e12		46
45	Prescription strategy of antimalarials in cutaneous and systemic lupus erythematosus: an international survey. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021 , 13, 1759720X211002595	3.8	2
44	Impact of Antimalarial Adherence on Mortality among Patients with Newly Diagnosed Systemic Lupus Erythematosus: A Population-based Cohort Study. <i>Arthritis Care and Research</i> , 2021 ,	4.7	4
43	Self-Reported Symptoms in a Cohort of Rheumatoid Arthritis and Systemic Lupus Erythematosus during the COVID-19 Quarantine Period. 2021 , 15, 16-23		0
42	Interventions for cutaneous disease in systemic lupus erythematosus. 2021 , 3, CD007478		4
41	Association of Higher Hydroxychloroquine Blood Levels With Reduced Thrombosis Risk in Systemic Lupus Erythematosus. 2021 , 73, 997-1004		7
40	Increased IL-23R Th Cells Population Exhibits Higher SLEDAI-2K Scores in Systemic Lupus Erythematosus Patients. <i>Frontiers in Immunology</i> , 2021 , 12, 690908	8.4	0
39	Recent progress in the treatment of lupus nephritis. 2012 , 22, 803-13		2
38	PHARMACOLOGY AND DRUG THERAPY. 2005 , 76-141		9

37	SYSTEMIC LUPUS ERYTHEMATOSUS. 2005 , 342-391		29
36	Clinical Features and Treatment of Systemic Lupus Erythematosus. 2009 , 1263-1300		4
35	Clinical impact of hydroxychloroquine dose adjustment according to the American Academy of Ophthalmology guidelines in systemic lupus erythematosus. <i>Lupus Science and Medicine</i> , 2020 , 7,	4.6	4
34	Flares in systemic lupus erythematosus: diagnosis, risk factors and preventive strategies. <i>Mediterranean Journal of Rheumatology</i> , 2017 , 28, 4-12	1.4	23
33	Expanding horizons for clinical applications of chloroquine, hydroxychloroquine, and related structural analogues. <i>Drugs in Context</i> , 2019 , 8,	5.2	25
32	Systemic lupus erythematosus in pregnancy--case report. <i>Medicinski Pregled</i> , 2005 , 58, 301-7	0.1	1
31	Pharmakotherapie. 2007 , 129-174		
30	Kollagenosen. 2010 , 99-127		
29	Treatment of non-renal lupus. 2011 , 1307-1316.e4		
28	Systemic Lupus Erythematosus in Elderly Populations. 2011 , 135-144		
27	Kollagenosen. 2012 , 103-131		
26	Systemic Lupus Erythematosus and the Kidney. 2014 , 153-181		
25	Pharmakotherapie. 2014 , 121-168		
24	Systemischer Lupus erythematosus. 2015 , H6d.1-H6d.4		0
23	Glomerular Diseases in Pregnancy. 2017 , 1-27		
22	Lupus Nephritis (Including Antiphospholipid Antibody Syndrome), Pediatric. 2018 , 1-35		
21	Factors Associated with Renal Outcomes in an Inception Cohort of Biopsy-proven Lupus Nephritis Patients. <i>Journal of Clinical Rheumatology and Immunology</i> , 2020 , 20, 9-20	0	
20	Antipalibicos de sntesis en dermatologā. <i>EMC - Dermatologā</i> , 2020 , 54, 1-11	0.1	

19	Predictors of unsuccessful hydroxychloroquine tapering and discontinuation: Can we personalize decision-making in systemic lupus treatment?. <i>Arthritis Care and Research</i> , 2020 ,	4.7	1
18	Utilization of health services and prescription patterns among lupus patients followed by primary care physicians and rheumatologists in Puerto Rico. <i>Ethnicity and Disease</i> , 2008 , 18, S2-205-10	1.8	6
17	A Young Lady with ANA negative SLE with Secondary Anti Phospholipid Syndrome. <i>Open Journal of Orthopedics and Rheumatology</i> , 2020 , 049-052	0.1	
16	Hydroxychloroquine and lupus flare: a good drug, but we need to do better.. <i>Annals of the Rheumatic Diseases</i> , 2022 ,	2.4	0
15	Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort.. <i>Annals of the Rheumatic Diseases</i> , 2021 ,	2.4	4
14	Hydroxychloroquine in systemic lupus erythematosus: overview of current knowledge.. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2022 , 14, 1759720X211073001	3.8	5
13	RetINal Toxicity And HydroxyChloroquine Therapy (INTACT): protocol for a prospective population-based cohort study.. <i>BMJ Open</i> , 2022 , 12, e053852	3	
12	Hydroxychloroquine in the pregnancies of women with lupus: a meta-analysis of individual participant data.. <i>Lupus Science and Medicine</i> , 2022 , 9,	4.6	1
11	Prevalence and factors associated with long-term remission in cutaneous lupus: a longitudinal cohort study of 141 cases.. <i>Journal of the American Academy of Dermatology</i> , 2022 ,	4.5	0
10	Mechanism of Action and Efficacy of Immunosuppressors in Lupus Nephritis.. <i>International Journal of Nephrology and Renovascular Disease</i> , 2021 , 14, 441-458	2.5	2
9	Hydroxychloroquine in the Pregnancies of Women with Lupus: A Meta-Analysis of Individual Participant Data.		
8	Understanding the Concept of Pre-Clinical Autoimmunity: Prediction and Prevention of Systemic Lupus Erythematosus: Identifying Risk Factors and Developing Strategies Against Disease Development. <i>Frontiers in Immunology</i> , 13,	8.4	2
7	Outcomes following antimalarial withdrawal in patients with quiescent systemic lupus erythematosus. <i>Seminars in Arthritis and Rheumatism</i> , 2022 , 55, 152046	5.3	
6	Risk of Arrhythmia among New Users of Hydroxychloroquine in RA and SLE : A Population-based Study.		
5	Development of a child-friendly oral drug formulation using liposomal multilamellar vesicle technology. 2022 , 625, 122107		
4	DNA Nanoflowers Amelioration of Lupus Symptoms in Mice via Blockade of TLR7/9 Signal. 2022 , 23, 16030		0
3	Management of Refractory Lupus Nephritis. 83-89		0
2	Systemic Lupus Erythematosus. 2023 , 167-212		0

- 1 Risk factors for mortality in 1528 Brazilian childhood-onset systemic lupus erythematosus patients. 096120332811705